Shopping Cart
Remove All
Your shopping cart is currently empty
Labetuzumab (Synonyms: IMMU-14, IMMU-100, hMN-14)
Catalog No. T9901A-004 Copy Product Info
🥰Excellent
Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC).
Labetuzumab
Copy Product Info🥰Excellent
Catalog No. T9901A-004
Synonyms IMMU-14, IMMU-100, hMN-14
Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC).
Cas No. 219649-07-7
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $347 | - | In Stock | |
| 2 mg | $476 | - | In Stock | |
| 5 mg | $695 | - | In Stock | |
| 10 mg | $1,090 | - | In Stock | |
| 25 mg | $1,660 | - | In Stock | |
| 50 mg | $2,230 | - | In Stock | |
| 100 mg | $2,950 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.2% (SDS-PAGE); 95.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with anticancer activity that inhibits tumor growth and is used in the study of thyroid and colorectal cancer (CRC). |
| In vivo | In vivo, Labetuzumab inhibits tumor growth following a single intravenous administration at a dose of 0.5 mg per rat [1]. |
| Synonyms | IMMU-14, IMMU-100, hMN-14 |
| Reactivity | Human |
| Verified Activity | Immobilized Human CEACAM5 Protein (His) (TMPY-01647) at 1 μg/mL (100 μL/well) can bind Labetuzumab. The EC50 is 10.180 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CEACAM5/CEA/CD66e |
| Molecular Weight | 145.1 kDa |
| Cas No. | 219649-07-7 |
| Relative Density. | no data available |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Labetuzumab | purchase Labetuzumab | Labetuzumab cost | order Labetuzumab | Labetuzumab chemical structure | Labetuzumab in vivo | Labetuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.